ADVM 241220 10.00C (ADVM241220C10000) Stock Options, News & Quotes

US OptionsDetailed Quotes

ADVM241220C10000

Watchlist

0.09
+0.04+80.00%

15min DelayClose Nov 27 16:00 ET

0.09High0.09Low

Intraday

5D
Daily

News

Mizuho Securities Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Cuts Target Price to $16
Moomoo NewsNov 22 14:31 ET · Ratings
Adverum Biotechnologies Price Target Lowered to $16 From $20 at Mizuho
TipRanksNov 22 13:45 ET
Mizuho Securities Cuts Price Target on Adverum Biotechnologies to $16 From $20, Outperform Rating Maintained
MT NewswiresNov 22 13:28 ET · Ratings
Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswireNov 20 16:05 ET
Express News | Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
ReutersNov 20 16:05 ET
Truist Financial Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating
Moomoo NewsNov 19 07:33 ET · Ratings

Comments

Stock_Drift

Nov 15 16:17

After Hours Ticks. 5:16pm 11/15🦌

$Scorpius Holdings (SCPX.US)$ $Perspective Therapeutics (CATX.US)$ $Turbo Energy (TURB.US)$ $Adverum Biotechnologies (ADVM.US)$ $NFT Ltd (MI.US)$ $Xylo Technologies (XYLO.US)$ $Lipocine (LPCN.US)$ $Massimo (MAMO.US)$ $China Jo-Jo Drugstores (CJJD.US)$ $Edesa Biotech (EDSA.US)$ $Atara Biotherapeutics (ATRA.US)$ $Eterna Therapeutics (ERNA.US)$ $DDC Enterprise (DDC.US)$
📊⚡️📊

Trytosaveabit

Aug 1 07:00

News

$Adverum Biotechnologies (ADVM.US)$ Reuters· just
Adverum Biotechnologies Announces FDA Regenerative Medicine Advanced Therapy (Rmat) Designation Granted for Ixo-Vec for the Treatment of Wet AMD

Jaguar8

Jul 17 02:57

NEWS

$Adverum Biotechnologies (ADVM.US)$
Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting
Adverum Biotechnologies (Nasdaq: ADVM) presented positive 26-week interim results from the LUNA Phase 2 trial of Ixo-vec for wet AMD at the 2024 ASRS Annual Meeting. Key findings include:
1. The 6E10 dose with local prophylaxis was selected for Phase 3 trials.
2. 76% of 6E10 patients were injection-fr...

Jaguar8

Apr 25 15:10

$Adverum Biotechnologies (ADVM.US)$
NEWS
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting

Trytosaveabit

Feb 8 06:05

Update

$Adverum Biotechnologies (ADVM.US)$ Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD
4 MINUTES AGO, 7:00 AM EST
VIA GLOBENEWSWIRE
– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and maintenance of both visual acuity and anatomic endpoints –
– Preliminary safety data support a favorable benefit-risk pr...